Mechanisms of trastuzumab induced cardiotoxicity - is exercise a potential treatment?

被引:25
作者
Eaton, Holden [1 ]
Timm, Kerstin Nina [2 ]
机构
[1] Univ Oxford, Merton Coll, Merton St, Oxford OX1 4JD, England
[2] Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England
关键词
Trastuzumab; Cardiotoxicity; Exercise; Metabolism; Chemotherapy; Heart failure; Cardioprotection; BREAST-CANCER PATIENTS; CHRONIC HEART-FAILURE; AEROBIC EXERCISE; CARDIAC DYSFUNCTION; LIFE-STYLE; RISK; ANTHRACYCLINE; MITOCHONDRIAL; INHIBITION; HER2;
D O I
10.1186/s40959-023-00172-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of the adjuvant therapeutic antibody trastuzumab in breast cancer is associated with a range of cardiotoxic side effects despite successfully reducing the severity of outcomes cancer patients,. The most common cardiac effect, a reduction in left ventricular ejection fraction (LVEF), is a known precursor to heart failure and often requires interruption of chemotherapy to avoid endangering patients further. An understanding of trastuzumab's cardiac-specific interactions is therefore critical in devising new methods to not only avoid permanent cardiac damage, but also prolong treatment time, and therefore effectiveness, for breast cancer patients. Increasingly, the use of exercise as a treatment has been indicated across the field of cardio-oncology due to encouraging evidence that it can protect against LVEF reductions and heart failure. This review explores the mechanisms of trastuzumab-mediated cardiotoxicity, as well as the physiological effects of exercise on the heart, in order to assess the suitability of exercise intervention for breast cancer patients on trastuzumab antibody-therapy. We furthermore draw comparison to existing evidence for exercise intervention as a cardioprotective treatment in doxorubicin-induced cardiotoxicity. Although preclinical evidence seems to support exercise-based approaches also in trastuzumab-cardiotoxicity, current clinical evidence is too limited to confidently recommend it as a treatment, largely owing to issues of adherence. Future studies should therefore examine how the variety and duration of exercise can be adjusted to improve treatment effectiveness at a more personalised level.
引用
收藏
页数:10
相关论文
共 50 条
[21]   Endothelial Dysfunction as a Determinant of Trastuzumab-mediated Cardiotoxicity in Patients with Breast Cancer [J].
Sandoo, Aamer ;
Kitas, George D. ;
Carmichael, Amtul R. .
ANTICANCER RESEARCH, 2014, 34 (03) :1147-1151
[22]   Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses [J].
Wang, Yunfang ;
Xu, Jianguo ;
Xie, Yafei ;
Zhou, Dan ;
Guo, Mingyue ;
Qin, Yu ;
Yi, Kang ;
Tian, Jinhui ;
You, Tao .
FRONTIERS IN PHARMACOLOGY, 2024, 15
[23]   Modulation of Anthracycline-Induced Cardiotoxicity by Aerobic Exercise in Breast Cancer Current Evidence and Underlying Mechanisms [J].
Scott, Jessica M. ;
Khakoo, Aarif ;
Mackey, John R. ;
Haykowsky, Mark J. ;
Douglas, Pamela S. ;
Jones, Lee W. .
CIRCULATION, 2011, 124 (05) :642-650
[24]   Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab [J].
Sendur, Mehmet A. N. ;
Aksoy, Sercan ;
Altundag, Kadri .
FUTURE ONCOLOGY, 2015, 11 (01) :13-15
[25]   Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer [J].
Nicolazzi, M. A. ;
Carnicelli, A. ;
Fuorlo, M. ;
Scaldaferri, A. ;
Masetti, R. ;
Landolfi, R. ;
Favuzzi, A. M. R. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (07) :2175-2185
[26]   A novel way to manage trastuzumab cardiotoxicity [J].
Hamdan, Diaddin ;
Darrouzain, Francois ;
Bejan-Angoulvant, Theodora ;
Isorni, Charles ;
Zelek, Laurent ;
Paintaud, Gilles ;
Janin, Anne ;
Bousquet, Guilhem .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) :791-796
[27]   In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity [J].
Beiranvand, Elham ;
Ostad, Seyed Nasser ;
Ardakani, Esmat Mirabzadeh ;
Torkashvand, Fatemeh ;
Sardari, Soroush ;
Vaziri, Behrouz .
DRUG RESEARCH, 2020, 70 (04) :165-169
[28]   Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy [J].
Mendez-Valdes, Gabriel ;
Gomez-Hevia, Francisca ;
Bragato, Maria Chiara ;
Lillo-Moya, Jose ;
Rojas-Sole, Catalina ;
Saso, Luciano ;
Rodrigo, Ramon .
ANTIOXIDANTS, 2023, 12 (02)
[29]   Acetylcholine receptor agonists effectively attenuated multiple program cell death pathways and improved left ventricular function in trastuzumab-induced cardiotoxicity in rats [J].
Arinno, Apiwan ;
Maneechote, Chayodom ;
Chunchai, Titikorn ;
Arunsak, Busarin ;
Kerdphoo, Sasiwan ;
Chattipakorn, Siriporn C. ;
Chattipakorn, Nipon .
LIFE SCIENCES, 2023, 329
[30]   Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention [J].
Bhagat, Anchit ;
Kleinerman, Eugenie S. .
CURRENT ADVANCES IN OSTEOSARCOMA: CLINICAL PERSPECTIVES: PAST, PRESENT AND FUTURE, 2ND EDITION, 2020, 1257 :181-192